Investment Type: Venture Capital
Portfolio 6
| Date | Name | Website | Total Raised | Location |
| 16.05.2023 | Boundless ... | boundlessbio.com | $251.4M | United Sta... |
| 06.05.2023 | ITM Isotop... | itm-radiopharma.com | $526.71M | Germany, B... |
| 02.08.2022 | IDRx | idrx.com | $242M | United Sta... |
| 22.09.2021 | Hexagon Bi... | hexagonbio.com | $232.3M | United Sta... |
| 24.08.2021 | Atavistik | atavistikbio.com | $100M | United Sta... |
| 07.10.2020 | A2 Biother... | a2biotherapeutics.com | $71.5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 12.09.2024 | Circle Pharma: $90 Million (Series D) Raised For Improving Oral Macrocycle Therapies | Circle Pharma, a clinical-stage biopharmaceutical company focused on discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round – which inclu... |
| 04.09.2024 | Circle Pharma Secures $90 Million to Propel Innovative Cancer Therapies | In the bustling heart of South San Francisco, Circle Pharma has struck gold. The clinical-stage biopharmaceutical company recently closed a $90 million Series D financing round. This infusion of capital is not just a financial boost; it’s a... |
| 03.09.2024 | Circle Pharma Closes $90M Series D Financing | Circle Pharma, a San Francisco, CA-based clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, raised $90M in Series D funding. The round was led by The Colu... |
| 13.08.2024 | IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies | IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financin... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cocktail therapies combine multiple drugs: Some hit parts of the replication machinery the virus uses to make copies of itself, others block its a... |
| 09.10.2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital. The company's shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech I... |
| 09.10.2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital. The company's shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech I... |
| 21.07.2016 | Nextech Invest Closes Oncology Fund IV, at $64M | Nextech Invest Ltd., a Zurich, Switzerland-based specialist oncology private equity investor, closed its fourth fund, at $64m. Oncology Fund IV, whose Limited Partners are based in the USA, Europe and Asia, will be invested in companies tha... |
Show more